This article is more than 5 years old. Information may no longer be current.
Noveome initiates phase 2 clinical trial for allergic conjunctivitis
Click Here to Manage Email Alerts
Noveome Biotherapeutics Inc. announced the initiation of a phase 2 clinical trial of ST266, the company’s novel secretome for treating patients with allergic conjunctivitis, according to a press release.
ST266 harnesses paracrine signaling and has been found to help promote cellular homeostasis, modulate inflammation and regenerate damaged cells, according to the company.
The phase 2 multicenter, double-masked, randomized, placebo-controlled trial will assess the efficacy, safety and tolerability of ST266 ophthalmic drops for treating the signs and symptoms of allergic conjunctivitis.
The trial will be conducted using Ora Inc.’s Conjunctival Allergen Challenge Model, which is accepted by the FDA as the standard methodology for evaluating the efficacy of products for allergic conjunctivitis, according to the release.
The primary endpoint of the study will measure ocular itching and conjunctival redness over time following an allergen challenge.
Earlier this year the company announced positive data from phase 1 trials of ST266 for the treatment of ocular and oral health conditions. All studies showed that ST266 was well tolerated, and no drug-related adverse events were reported, according to the release.